Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation
Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed
after first-line treatment